← Back to Screener
Alterity Therapeutics Limited American Depositary Shares (ATHE)
Price$3.90
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-14.59%
Price vs S&P 500 (4W)-15.99%
VGM Score58.85
Market Capitalization$60.02M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)2.72x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)463.07%
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)-3.16%
Net Profit Margin (TTM)-1172.16%
EPS (TTM)$-0.00
10-Day Avg Trading Volume0.41M
EPS Excl Extra (TTM)$-0.00
Revenue Growth (5Y)91.97%
EPS (Annual)$-0.00
ROI (Annual)-36.10%
Net Profit Margin (5Y Avg)-136347.96%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)717.39%
ROA (Last FY)-31.06%
Revenue Growth TTM (YoY)376.33%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-80.12%
Operating Margin (TTM)-1337.31%
Cash Flow / Share (Annual)$-0.00
P/B Ratio1.56x
P/B Ratio (Quarterly)1.60x
Net Income / Employee (Annual)$-955,016
EV / Revenue (TTM)28.70x
Net Interest Coverage (TTM)-179.00x
ROA (TTM)-28.35%
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)7.07x
Quick Ratio (Quarterly)21.98x
3-Month Avg Trading Volume0.18M
52-Week Price Return-30.00%
Revenue / Employee (TTM)$97,851
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)190.07x
Asset Turnover (Annual)0.00x
52-Week High$0.88
Operating Margin (5Y Avg)-162219.75%
EPS Excl Extra (Annual)$-0.00
Tangible BV CAGR (5Y)5.72%
26-Week Price Return-6.67%
Quick Ratio (Annual)6.79x
13-Week Price Return5.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)21.98x
Enterprise Value$25.28M
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-19.83%
Revenue / Employee (Annual)$35,093
Pretax Margin (Annual)-2706.71%
Cash / Share (Annual)$0.01
3-Month Return Std Dev8668.55%
Net Income / Employee (TTM)$-1,146,967
ROE (Last FY)-36.22%
Net Interest Coverage (Annual)-509.65x
EPS Basic Excl Extra (Annual)$-0.00
Receivables Turnover (TTM)26.83x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.00
Receivables Turnover (Annual)17.24x
ROI (TTM)-30.11%
P/S Ratio (TTM)68.15x
Pretax Margin (5Y Avg)-135654.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.05
Price vs S&P 500 (52W)-54.37%
Year-to-Date Return5.00%
5-Day Price Return-6.67%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-63.71%
Net Profit Margin (Annual)-2721.96%
Month-to-Date Return4100.00%
Cash Flow / Share (TTM)$-0.00
EBITD / Share (Annual)$-0.00
Operating Margin (Annual)-3185.21%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-79.89%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.00
P/TBV (Quarterly)1.00x
P/B Ratio (Annual)0.88x
Pretax Margin (TTM)-1161.75%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)-3.25%
Beta0.76x
Revenue / Share (TTM)$0.00
ROE (TTM)-30.19%
52-Week Low$0.01
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ATHEAlterity Therapeutics Limited American Depositary Shares | D | A | C | $3.90 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Alterity Therapeutics is a clinical-stage biotechnology company developing novel treatments for Parkinson's disease and other neurodegenerative disorders. The company's proprietary pipeline targets the underlying pathology of these diseases through compounds designed to bind excess iron, reduce alpha-synuclein aggregation, and restore neuronal function. Lead programs include ATH434 and related candidates, supported by a broader drug discovery platform.